Centre proposes faster clearances for domestic drug studies and import test licences
The government has proposed prior intimation instead of approval for eligible domestic BA/BE studies and a 45-working-day timeline for import test licences, down from 90 days. Vaccines, biologics, narcotics and other high-risk products would continue to require formal licences.
What happened
Government of India · Centre proposes allowing prior intimation instead of approval for eligible domestic drug BA/BE studies and cutting import-test licence
Key facts
- 90 working days
- 45 working days
- Rules 67, 68, 69 and 70
- New Drugs and Clinical Trials Rules 2019
Why this matters
Accelerated study and test-import pathways could make Indian generic pipelines, CRO partnerships and targeted licensing deals more attractive, especially for lower-risk molecules.
What to watch
- DTAB recommendation and publication of the final Drugs Rules amendment or implementing guidance.
- Final definition of eligible BA/BE studies, products and sponsors, including whether the prior-intimation route has post-submission hold powers.
- Evidence that the 45-working-day import test-licence service standard is binding, digitally tracked and supported by deemed approval or escalation mechanisms.
- Monthly CDSCO data on application volumes, processing times, queries and rejection rates after implementation.
- Generic-company commentary on accelerated BA/BE starts, abbreviated development timelines and domestic launch calendars.
- Retail pharmacy evidence of lower stock-outs, increased supplier bids, new SKU launches or improved gross-margin terms in affected therapies.
- Map listed and private generic suppliers with high domestic BA/BE-study intensity and frequent importation of reference samples, standards or test materials.
- Ask pharmacy procurement teams which high-volume chronic and acute therapy categories have the deepest pending generic-launch pipelines and greatest current supply concentration.
- Model a modest 6-18 month improvement in launch timing rather than an immediate broad reduction in medicine prices.
- Track whether organized pharmacy retailers use new supplier options to negotiate better trade terms, improve private-label/house-brand sourcing or reduce stock-out risk.
- Separate exposure to eligible conventional generics from vaccines, biologics, narcotics and other high-risk categories that remain under formal licensing.